LGND Stock Overview
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Ligand Pharmaceuticals Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$71.00 |
| 52 Week High | US$94.57 |
| 52 Week Low | US$49.24 |
| Beta | 0.92 |
| 1 Month Change | 2.53% |
| 3 Month Change | -5.70% |
| 1 Year Change | -8.47% |
| 3 Year Change | -51.60% |
| 5 Year Change | -43.53% |
| Change since IPO | 18.33% |
Recent News & Updates
Recent updates
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar
Dec 19
Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?
Jun 14We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?
May 07These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27Ligand Pharmaceuticals: Moving Parts Keep Moving
Mar 29We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease
Mar 17Ligand: Green Shoots And A Hidden Treasure - A Spinoff Bonus For The New Year
Dec 31Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?
Dec 03Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 38% Discount?
Oct 11Ligand's Ailing Remdesivir Cash Cow
Oct 11Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?
Aug 19Shareholder Returns
| LGND | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -10.0% | 0.08% | 1.2% |
| 1Y | -8.5% | 13.2% | 24.9% |
Return vs Industry: LGND underperformed the US Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: LGND underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| LGND volatility | |
|---|---|
| LGND Average Weekly Movement | 7.8% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LGND's share price has been volatile over the past 3 months.
Volatility Over Time: LGND's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 58 | Scott Plesha | www.ligand.com |
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19.
Ligand Pharmaceuticals Incorporated Fundamentals Summary
| LGND fundamental statistics | |
|---|---|
| Market cap | US$1.24b |
| Earnings (TTM) | US$53.82m |
| Revenue (TTM) | US$131.31m |
23.4x
P/E Ratio9.6x
P/S RatioIs LGND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LGND income statement (TTM) | |
|---|---|
| Revenue | US$131.31m |
| Cost of Revenue | US$35.05m |
| Gross Profit | US$96.27m |
| Other Expenses | US$42.45m |
| Earnings | US$53.82m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | 3.04 |
| Gross Margin | 73.31% |
| Net Profit Margin | 40.99% |
| Debt/Equity Ratio | 0% |
How did LGND perform over the long term?
See historical performance and comparison